Back
Regeneron Pharmaceuticals 10K Form
Buy
59
REGN
Regeneron Pharmaceuticals
Last Price:
825.08
Seasonality Move:
4.56%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-05 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2020-05-05 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2020-02-07 | 10K | REGN/Regeneron Pharmaceuticals Annual |
| 2019-11-05 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2019-08-06 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2019-05-07 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
Receive REGN News And Ratings
See the #1 stock for the next 7 days that we like better than REGN
REGN Financial Statistics
Sales & Book Value
| Annual Sales: | $12.17B |
|---|---|
| Cash Flow: | $888.5M |
| Price / Cash Flow: | 31.22 |
| Annual Sales: | $220.55 |
| Price / Book: | 3.73 |
Profitability
| EPS (TTM): | 37.83000 |
|---|---|
| Net Income (TTM): | $4.3B |
| Gross Margin: | $10.61B |
| Return on Equity: | 19.14% |
| Return on Assets: | 14.84% |
Regeneron Pharmaceuticals Earnings Forecast
Key Regeneron Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 33 years for REGN is 87.18%.
- The Selling, General & Administrative Expenses for REGN have been equal to 17.38% of Gross Profit Margin.
- The Research & Development expenses have been 31.61% of Revenue.
- The Interest Expense is 1.37% of Operating Income.
- The Net Earning history of REGN is 35.64% of Total Revenues.
- Per Share Earnings over the last 33 years have been positive in 18 years.
Regeneron Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Current Symbol: | REGN |
| CUSIP: | 75886F |
| Website: | regeneron.com |
Debt
| Debt-to-Equity Ratio: | 0.08 |
|---|---|
| Current Ratio: | 5.45 |
| Quick Ratio: | 4.53 |
Price-to-Earnings
| Trailing P/E Ratio: | 21.58 |
|---|---|
| Forward P/E Ratio: | 18.8 |
REGN Technical Analysis vs Fundamental Analysis
Buy
59
Regeneron Pharmaceuticals (REGN)
is a Buy
Is Regeneron Pharmaceuticals a Buy or a Sell?
-
Regeneron Pharmaceuticals stock is rated a Buy
The current Regeneron Pharmaceuticals [REGN] share price is $824.84. The Score for REGN is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.